Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Ratutrelvir (83-0060) non-randomised, Ratutrelvir non-randomised, Ratutrelvir (83-0060)
Ratutrelvir · 1 trial · 1 indication
Adverse events incidence will be described using descriptive statistics methods
Adverse events severity will be assessed by current version of CTCAE
| Arm | Type | Description |
|---|---|---|
| Ratutrelvir (83-0060) non-randomised | EXPERIMENTAL | - |
| Paxlovid | ACTIVE_COMPARATOR | Standard of care |
| Ratutrelvir (83-0060) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Ratutrelvir (83-0060) non-randomised | DRUG | 83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL) |
| Paxlovid | DRUG | Paxlovid (Nirmatrelvir+ Ritonavir , boosted 3CL-protease inhibitor) |
| Ratutrelvir (83-0060) | DRUG | 83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL) |
Inclusion Criteria: 1. Confirmed SARS-CoV-2 infection for 120 h prior to randomization. 2. Initial onset of signs/symptoms attributable to COVID-19 within 5 days prior to randomization. 3. At least one of the symptoms attributable to COVID-19 present within 24 hours prior to the Day 1 with the seve...
Top 9 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | ibuzatrelvir, Nirmatrelvir/ ritonavir, BNT162b2/RIV |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Molnupiravir |
| Invivyd, Inc. | IVVD | 2 | PHASE3 | VYD2311 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Tradipitant |
| Moderna, Inc. | MRNA | 2 | PHASE2 | mRNA-1283, mRNA-1273 |
| ImmunityBio Inc | IBRX | 2 | PHASE2 | Nogapendekin alfa inbakicept |
| Traws Pharma, Inc. | TRAW | 1 | PHASE2 | Ratutrelvir |
| GeoVax Labs, Inc. | GOVX | 1 | PHASE2 | GEO-CM04S1 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE2 | Remdesivir |
Ratutrelvir is an investigational small molecule antiviral being developed for the treatment of mild to moderate COVID-19 in adults. It is not yet approved for any indication and remains in clinical development. Traws Pharma, Inc. is studying it in an early-stage Phase 2 trial in patients aged 18 years and older.
Ratutrelvir is being developed by Traws Pharma, Inc., which trades under the ticker TRAW. The company is the sponsor of the clinical program evaluating the drug in COVID-19.
Ratutrelvir is in Phase 2 clinical development. It is investigational and has not been approved by the FDA or any other regulatory authority. The ongoing Phase 2 study is currently recruiting participants.
Ratutrelvir is being evaluated in one active clinical trial, NCT07157007, titled Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. The Phase 2 study is recruiting and plans to enroll 90 participants across Australia, South Korea, Taiwan, and Uzbekistan.
Yes. Ratutrelvir is also referred to as Ratutrelvir (83-0060) and Ratutrelvir non-randomised. These are alternative names for the same investigational small molecule antiviral developed by Traws Pharma, Inc. for COVID-19.
The Phase 2 trial NCT07157007 is an active-controlled study of Ratutrelvir in adults with mild to moderate COVID-19. It is randomized but not double-blind, is not biomarker-selected, and does not enroll healthy volunteers. The study plans to enroll 90 participants and is currently recruiting.